Search

Your search keyword '"M. Bielska-Lasota"' showing total 2 results
Start Over Author "M. Bielska-Lasota" Search Limiters Peer Reviewed
2 results on '"M. Bielska-Lasota"'

1. Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes

Author

Elena Demuru, Silvia Rossi, Leonardo Ventura, Luigino Dal Maso, Stefano Guzzinati, Alexander Katalinic, Sebastien Lamy, Valerie Jooste, Corrado Di Benedetto, Roberta De Angelis, the EUROCARE-6 Working Group, M. Hackl, E. Van Eycken, N. Van Damme, Z. Valerianova, M. Sekerija, V. Scoutellas, A. Demetriou, L. Dušek, D. Krejici, H. Storm, M. Mägi, K. Innos, N. Malila, J. Pitkäniemi, M. Velten, X. Troussard, A.M. Bouvier, V. Jooste, A.V. Guizard, S. Dabakuyo Yonli, M. Maynadié, J.B. Nousbaum, G. Coureau, A. Monnereau, I. Baldi, K. Hammas, B. Tretarre, M. Colonna, S. Plouvier, T. D’Almeida, F. Molinié, A. Cowppli-Bony, S. Bara, G. Defossez, B. LapÔtre-Ledoux, P. Grosclaude, L. Daubisse-Marliac, S. Luttmann, R. Stabenow, A. Nennecke, J. Kieschke, S. Zeissig, B. Holleczek, A. Katalinic, H. Birgisson, D. Murray, P.M. Walsh, G. Mazzoleni, F. Vittadello, F. Cuccaro, R. Galasso, G. Sampietro, S. Rosso, C. Gasparotti, G. Maifredi, M. Ferrante, R. Ragusa, M.L. Gambino, M. Lanzoni, P. Ballotari, E. Giacomazzi, S. Ferretti, A. Caldarella, G. Manneschi, G. Gatta, M. Sant, P. Baili, F. Berrino, L. Botta, A. Trama, R. Lillini, A. Bernasconi, L. Bonfarnuzzo, C. Vener, F. Didoné, P. Lasalvia, G. Del Monego, L. Buratti, G. Tagliabue, D. Serraino, L. Dal Maso, R. Capocaccia, R. De Angelis, E. Demuru, C. Di Benedetto, S. Rossi, M. Santaquilani, S. Venanzi, M. Tallon, L. Boni, S. Iacovacci, V. Gennaro, A.G. Russo, F. Gervasi, G. Spagnoli, L. Cavalieri d’’Oro, M. Fusco, M.F. Vitale, M. Usala, W. Mazzucco, M. Michiara, G. Chiranda, G. Cascone, C.P. Rollo, L. Mangone, F. Falcini, R. Cavallo, D. Piras, A. Madeddu, F. Bella, A.C. Fanetti, S. Minerba, G. Candela, T. Scuderi, R.V. Rizzello, M. Rugge, A. Brustolin, S. Pildava, G. Smailyte, M. Azzopardi, T.B. Johannesen, J. Didkowska, U. Wojciechowska, M. Bielska-Lasota, A. Pais, J. Rodrigues, M.J. Bento, A. Miranda, V. Zadnik, T. Zagar, C. Sánchez-Contador Escudero, P. Franch Sureda, A. Lopez de Munain, M. De-La-Cruz, M.D. Rojas, A. Aleman, A. Vizcaino, R. Marcos-Gragera, A. Sanvisens, M.J. Sanchez, M.D. Chirlaque, A. Sanchez-Gil, M. Guevara, E. Ardanaz, A. Ameijide, C. Carulla, Y. Bergeron, C. Bouchardy, S. Mohsen Mousavi, P. Went, M. Blum, A. Bordoni, O. Visser, S. Stevens, J. Broggio, A. Gavin, D. Morrison, and D.W. Huws

Subjects
cancer prevalence, cancer registries, cancer survivors, cancer survivorship, EUROCARE, Europe, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

IntroductionComparable indicators on complete cancer prevalence are increasingly needed in Europe to support survivorship care planning. Direct measures can be biased by limited registration time and estimates are needed to recover long term survivors. The completeness index method, based on incidence and survival modelling, is the standard most validated approach.MethodsWithin this framework, we consider two alternative approaches that do not require any direct modelling activity: i) empirical indices derived from long established European registries; ii) pre-calculated indices derived from US-SEER cancer registries. Relying on the EUROCARE-6 study dataset we compare standard vs alternative complete prevalence estimates using data from 62 registries in 27 countries by sex, cancer type and registration time.ResultsFor tumours mostly diagnosed in the elderly the empirical estimates differ little from standard estimates (on average less than 5% after 10-15 years of registration), especially for low prognosis cancers. For early-onset cancers (bone, brain, cervix uteri, testis, Hodgkin disease, soft tissues) the empirical method may produce substantial underestimations of complete prevalence (up to 20%) even when based on 35-year observations. SEER estimates are comparable to the standard ones for most cancers, including many early-onset tumours, even when derived from short time series (10-15 years). Longer observations are however needed when cancer-specific incidence and prognosis differ remarkably between US and European populations (endometrium, thyroid or stomach).DiscussionThese results may facilitate the dissemination of complete prevalence estimates across Europe and help bridge the current information gaps.

Published
2023
Full Text
View/download PDF

2. Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials

Author

Claudia Vener, Silvia Rossi, Pamela Minicozzi, Rafael Marcos-Gragera, Hélène A. Poirel, Marc Maynadié, Xavier Troussard, Gabriella Pravettoni, Roberta De Angelis, Milena Sant, the EUROCARE-6 Working Group, M. Hackl, E. Van Eycken, Z. Valerianova, M. Sekerija, P. Pavlou, L. Dušek, H. Storm, M. Mägi, K. Innos, N. Malila, J. Pitkäniemi, M. Velten, X. Troussard, A.M. Bouvier, V. Jooste, A.V. Guizard, G. Launoy, S. Dabakuyo Yonli, M. Maynadié, A.S. Woronoff, J.B. Nousbaum, G. Coureau, A. Monnereau, I. Baldi, K. Hammas, B. Tretarre, M. Colonna, S. Plouvier, T. D’Almeida, F. Molinié, A. Cowppli-Bony, S. Bara, C. Schvartz, G. Defossez, B. Lapôtre-Ledoux, P. Grosclaude, S. Luttmann, R. Stabenow, A. Nennecke, J. Kieschke, S. Zeissig, B. Holleczek, A. Katalinic, H. Birgisson, D. Murray, P.M. Walsh, G. Mazzoleni, F. Vittadello, F. Cuccaro, R. Galasso, G. Sampietro, S. Rosso, M. Magoni, M. Ferrante, A. Sutera Sardo, M.L. Gambino, P. Ballotari, E. Giacomazzi, S. Ferretti, A. Caldarella, G. Manneschi, G. Gatta, M. Sant, P. Baili, F. Berrino, L. Botta, A. Trama, R. Lillini, A. Bernasconi, S. Bonfarnuzzo, C. Vener, F. Didonè, P. Lasalvia, G. Del Monego, M.C. Magri, L. Buratti, D. Serraino, L. Dal Maso, R. Capocaccia, R. De Angelis, E. Demuru, C. Di Benedetto, S. Rossi, M. Santaquilani, S. Venanzi, R.A. Filiberti, S. Iacovacci, V. Gennaro, A.G. Russo, G. Spagnoli, L. Cavalieri d’Oro, M. Fusco, M.F. Vitale, M. Usala, F. Vitale, M. Michiara, G. Chiranda, G. Cascone, E. Spata, L. Mangone, F. Falcini, R. Cavallo, D. Piras, A. Madeddu, F. Bella, A.C. Fanetti, S. Minerba, G. Candela, T. Scuderi, R.V. Rizzello, F. Stracci, G. Tagliabue, M. Rugge, A. Brustolin, S. Pildava, G. Smailyte, M. Azzopardi, T.B. Johannesen, J. Didkowska, U. Wojciechowska, M. Bielska-Lasota, A. Pais, J.L. Pontes, A. Miranda, C. Safaei Diba, V. Zadnik, T. Zagar, C. Sánchez-Contador Escudero, P. Franch Sureda, A. Lopez de Munain, M. De-La-Cruz, M.D. Rojas, A. Aleman, A. Vizcaino, R. Marcos-Gragera, M.J. Sanchez, M.D. Chirlaque, M. Guevara Eslava, E. Ardanaz, J. Galceran, M. Carulla, Y. Bergeron, C. Bouchardy, S. Mohsen Mousavi, A. Bordoni, O. Visser, J. Rashbass, A. Gavin, D. Morrison, and D. W. Huws

Subjects
cancer registries, chronic myeloid leukemia (CML), randomized controlled trials (RCTs), real-world data, survival, Europe, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This raises questions on the added value of results from population-based studies, which use real-world data, compared to results of randomized controlled trials (RCTs) involving patients with CML. There are also questions about the extent of the findings on RCTs effectiveness for patients in the general population. We compare survival data extracted from our previous systematic review and meta-analysis of CML RCTs with the latest updated population-based survival data of EUROCARE-6, the widest collaborative study on cancer survival in Europe. The EUROCARE-6 CML survival estimated in patients (15–64 years) diagnosed in 2000–2006 vs. 2007–2013 revealed that the prognostic improvement highlighted by RCTs was confirmed in real-world settings, too. The study shows, evaluating for the first time all European regions, that the optimal outcome figures obtained in controlled settings for CML are also achievable (and indeed achieved) in real-world settings with prompt introduction of TKIs in daily clinical practice. However, some differences still persist, particularly in Eastern European countries, where overall survival values are lower than elsewhere, probably due to a delayed introduction of TKIs. Our results suggest an insufficient adoption of adequate protocols in daily clinical practice in those countries where CML survival values remain lower in real life than the values obtained in RCTs. New high-resolution population-based studies may help to identify failures in the clinical pathways followed there.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results